Dexmethylphenidate controlled release - Cingulate Therapeutics
Alternative Names: CTX-1301; Dexmethylphenidate HClLatest Information Update: 16 Oct 2024
At a glance
- Originator Cingulate Therapeutics
- Developer Bio-Images Drug Delivery; Cingulate Therapeutics
- Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Attention-deficit hyperactivity disorder
Most Recent Events
- 12 Sep 2024 Cingulate Therapeutics commenced its final FDA-required study (Food effect study) for CTx 1301 in attention deficit hyperactivity disorder (ADHD)
- 16 Aug 2024 Cingulate Therapeutics terminates a phase III trial for Attention-deficit hyperactivity disorder (In children) in USA (PO), due to continuation of the study is not required for NDA submission via the 505(b) pathway (NCT0594594)
- 15 Aug 2024 Cingulate Therapeutics has patent protection for dexmethylphenidate controlled release in European union and United Kingdom